GlassScriptPhysician profile
Malinda M Moussa
NPI 1801831698
$2,338.38
in general payments reported to CMS, 2019-2025
28 companies · $329 in 2025
The $329 reported for 2025 was more than what a typical Obstetrics & Gynecology (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Obstetrics & Gynecology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $514 · 2022: $699 · 2023: $560 · 2024: $237 · 2025: $329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,125.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $499.26 | 2021-2023 | |
| Mayne Pharma Commercial LLC | $297.20 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $174.48 | 2021-2025 | |
| Hologic Sales and Service, LLC | $163.27 | 2021-2025 | Aptima, Thinprep 2000 Processor |
| Eisai INC. | $113.24 | 2021 | |
| Shield Therapeutics INC | $108.77 | 2022-2023 | Accrufer |
| Therapeuticsmd, INC. | $98.92 | 2021-2022 | |
| Scynexis, INC. | $95.93 | 2022 | |
| Sumitomo Pharma America, INC. | $95.50 | 2023-2025 | Myfembree, Gemtesa |
| Novo Nordisk INC | $86.19 | 2022-2024 | Wegovy |
| Pfizer INC. | $83.52 | 2021-2024 | |
| Astellas Pharma US INC | $75.27 | 2025 | Veozah |
| Exact Sciences Corporation | $67.94 | 2023-2025 | Cologuard Collection Kit |
| Organon LLC | $63.71 | 2022-2023 | Nexplanon |
| Avion Pharmaceuticals | $61.91 | 2022-2023 | Balcoltra |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $32.14 | 2024-2025 | Femlyv, Femring, Intrarosa |
| Abbott Laboratories | $27.57 | 2023 | Proclaim |
| Exeltis, USA INC. | $26.40 | 2022-2024 | Slynd |
| Medtronic, INC. | $20.10 | 2024 | V-Loc 180 |
| Lsi Solutions INC | $19.75 | 2024 | Fornisee |
| Evofem Biosciences, INC. | $19.61 | 2022 | |
| Coopersurgical, INC. | $17.43 | 2023 | Paragard T 380a |
| Mycovia Pharmaceuticals, INC. | $17.17 | 2022 | |
| Myovant Sciences INC. | $17.09 | 2022 | |
| Channel Medsystems, INC. | $14.79 | 2023 | |
| Becton, Dickinson and Company | $14.18 | 2022 | |
| Sage Therapeutics, LLC | $13.71 | 2022 | |
| Agile Therapeutics, INC. | $13.33 | 2024 | Twirla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malinda Moussa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.